Skip to main content

Table 4 Patients' demographic and clinical characteristics according to mitochondrial DNA haplogroup

From: Survival and mitochondrial function in septic patients according to mitochondrial DNA haplogroup

  Other haplogroups (n= 81) JT haplogroup (n= 15) P value
Gender male 52 (64.2) 8 (53.3) 0.56
Age (years) 59 (48 to 68) 64 (54 to 81) 0.11
Diabetes mellitus 32 (39.5) 4 (26.7) 0.40
COPD 9(11.1) 1 (6.7) 0.99
Ischemic heart disease 6 (7.4) 1 (6.7) 0.99
Ischemic stroke 3 (3.7) 0 0.99
Site of infection    0.96
   Respiratory 54 (66.7) 8 (53.3)  
   Abdominal 16 (19.8) 5 (33.3)  
   Urinary 3 (3.7) 1 (6.7)  
   Skin 5 (6.2) 1 (6.7)  
   Endocarditis 2 (2.5) 0  
   Others 1 (1.2) 0  
Microorganism responsible    
   Unknown 43 (53.1) 6 (40.0) 0.41
   Gram-positive 19 (23.5) 5 (33.3) 0.52
   Gram-negative 18 (22.2) 4 (26.7) 0.74
   Fungi 4 (4.9) 0 0.99
   Anaerobe 1 (1.2) 0 0.99
Bloodstream infection 10 (12.3) 3 (20.0) 0.42
Empiric antimicrobial treatment    0.81
   Unknown if adequate due to negative cultures 42 (51.9) 7 (46.7)  
   Adequate 32 (39.5) 6 (40.0)  
   Unknown if adequate due to diagnosis by antigenuria 6 (7.4) 2 (13.3)  
   Inadequate 1 (1.2) 0  
β-lactamic more aminoglycoside 17 (21.0) 3 (20.0) 0.30
β-lactamic more quinolone 46 (56.8) 6 (40.0) 0.58
Mean blood pressure (mmHg) 68 (63 to 71) 69 (63 to 75) 0.74
Septic shock 70 (86.4) 13 (86.7) 0.99
Norepinephrine 70 (86.4) 13 (86.7) 0.99
Norepinephrine dose (μg/kg/minute) 0.5 (0.3 to 0.8) 0.5 (0.4 to 0.9) 0.75
Dobutamine 6 (7.4) 1 (6.7) 0.99
Dobutamine dose (μg/kg/minute) 6.0 (5.0 to 8.0) 5.0 0.57
PaO2/FIO2 ratio 160 (102 to 265) 138 (84 to 197) 0.98
Creatinine (mg/dl) 1.20 (0.70 to 2.00) 2.05 (1.10 to 3.07) 0.35
Bilirubin (mg/dl) 1.00 (0.55 to 2.30) 0.92 (0.48 to 1.44) 0.54
Leukocytes (×103/mm3) 12.2 (5.4 to 19.9) 16.4 (8.5 to 25.9) 0.82
Lactic acid (mmol/l) 2.20 (1.30 to 4.37) 3.80 (1.70 to 4.65) 0.20
Platelets (×103/mm3) 180 (89 to 266) 120 (43 to 193) 0.28
INR 1.32 (1.11 to 1.56) 1.24 (1.15 to 1.67) 0.35
aPTT (seconds) 33 (29 to 42) 36 (26 to 49) 0.30
APACHE II score 20 (16 to 25) 21 (18 to 23) 0.98
SOFA score 9 (7 to 12) 9 (8 to 12) 0.78
Survivors at 180 days 43 (53.1) 11 (73.3) 0.17
Survivors at 30 days 50 (61.7) 13 (86.7) 0.08
  1. Data presented as number (percentage) or median (interquartile range). COPD, chronic obstructive pulmonary disease; PaO2/FIO2, pressure of arterial oxygen/fraction inspired oxygen; aPTT, activated partial thromboplastin time; INR, International Normalized Ratio; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sepsis-related Organ Failure Assessment.